External validation of predictive models of sexual, urinary, bowel and hormonal function after surgery in prostate cancer subjects

Author:

Borg Matthew A.ORCID,O’Callaghan Michael E.ORCID,Moretti Kim L.ORCID,Vincent Andrew D.ORCID

Abstract

Abstract Background In 2020, a research group published five linear longitudinal models, predict Expanded Prostate Cancer Index Composite-26 (EPIC-26) scores post-treatment for radical prostatectomy, external beam radiotherapy and active surveillance collectively in US patients with localized prostate cancer. Methods Our study externally validates the five prediction models for patient reported outcomes post-surgery for localised prostate cancer. The models’ calibration, fit, variance explained and discrimination (concordance-indices) were assessed. Two Australian validation cohorts 1 and 2 years post-prostatectomy were constructed, consisting of 669 and 439 subjects, respectively (750 in total). Patient reported function in five domains post-prostatectomy: sexual, bowel, hormonal, urinary incontinence and other urinary dysfunction (irritation/obstruction). Domain function was assessed using the EPIC-26 questionnaire. Results 1 year post-surgery, R2 was highest for the sexual domain (35%, SD = 0.02), lower for the bowel (21%, SD = 0.03) and hormone (15%, SD = 0.03) domains, and close to zero for urinary incontinence (1%, SD = 0.01) and irritation/obstruction (− 5%, SD = 0.04). Calibration slopes for these five models were 1.04 (SD = 0.04), 0.84 (SD = 0.06), 0.85 (SD = 0.06), 1.16 (SD = 0.13) and 0.45 (SD = 0.04), respectively. Calibration-in-the-large values were − 2.2 (SD = 0.6), 2.1 (SD = 0.01), 5.1 (SD = 0.1), 9.6 (SD = 0.9) and 4.0 (SD = 0.2), respectively. Concordance-indices were 0.73, 0.70, 0.70, 0.58 and 0.62, respectively (all had SD = 0.01). Mean absolute error and root mean square error were similar across the validation and development cohorts. The validation measures were largely similar at 2 years post-surgery. Conclusions The sexual, bowel and hormone domain models validated well and show promise for accurately predicting patient reported outcomes in a non-US surgical population. The urinary domain models validated poorly and may require recalibration or revision.

Publisher

Springer Science and Business Media LLC

Subject

Urology,Reproductive Medicine,General Medicine

Reference30 articles.

1. Cancer Australia. Prostate cancer in Australia statistics. Canberra, Australia: Australian Government 2021 Available from: https://www.canceraustralia.gov.au/affected-cancer/cancer-types/prostate-cancer/statistics

2. Leslie SW, Soon-Sutton TL, IA R, Sajjad H, Siref LE, Prostate Cancer. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.

3. Sebesta EM, Anderson CB. The surgical Management of Prostate Cancer. Semin Oncol. 2017;44(5):347–57. https://doi.org/10.1053/j.seminoncol.2018.01.003.

4. Mottet N, Cornford P, van den Bergh RCN, Briers E, Eberli D, De Meerleer G, et al. Prostate Cancer Arnhem. Netherlands Euorp Assoc Urol. 2023; Available from: https://uroweb.org/guidelines/prostate-cancer

5. Weldring T, Smith SMS. Article Commentary: Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs), vol. 6. Health Services Insights; 2013. p. HSI.S11093. https://doi.org/10.4137/hsi.s11093.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3